Current Status of Compounding of Tirzepatide: With respect to the current status of compounding of tirzepatide, FDA noted that it wished to avoid unnecessary disruption to patient treatment, and outlined the current enforcement policy moving forward: [T]he agency does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on tirzepatide injection products inclusion on FDAs drug shortage list: For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from todays announcement, until February 18, 2025
If you lose weight too quickly (especially if you have held excess body fat for a prolonged period of time), skin can't reshape itself to your new form as it normally would over an extended period of time, experts maintain
This process helps reduce fat deposits, particularly in stubborn areas
Altered gut microbiota in type 2 diabetes: just a coincidence
doi:10.1016/j.intimp.2019.106174 5